Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2014 | 1 |
2016 | 1 |
2018 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.
Cancer Res. 2016 Jun 1;76(11):3387-96. doi: 10.1158/0008-5472.CAN-15-2698. Epub 2016 Apr 5.
Cancer Res. 2016.
PMID: 27197189
Free PMC article.
Lymphoma-prone AKT2-transgenic or PTEN-deficient mice on an Rpl22(-/-) background developed significantly larger and markedly more vascularized thymic tumors than those observed in Rpl22(+/+) control mice. But, unlike Rpl22(+/+) or Rpl22(+/-) tumors, Rpl22(-/-) lymphomas d …
Lymphoma-prone AKT2-transgenic or PTEN-deficient mice on an Rpl22(-/-) background developed significantly larger and markedly more vasculari …
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.
Wicki A, et al.
Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13.
Eur J Cancer. 2018.
PMID: 29660598
Clinical Trial.
PK shows fast absorption (T(max) 1-2 h) and dose proportionality for C(max) and area under the curve. A partial response in a patient with metastatic thymus cancer, 24% disease volume reduction in a patient with sinonasal cancer and stable disease for more than 16 w …
PK shows fast absorption (T(max) 1-2 h) and dose proportionality for C(max) and area under the curve. A partial response in a patient with m …
Item in Clipboard
Excessive risk of cancer and in particular lymphoid malignancy in myasthenia gravis patients: a population-based cohort study.
Yeh JH, Lin CC, Chen YK, Sung FC, Chiu HC, Kao CH.
Yeh JH, et al.
Neuromuscul Disord. 2014 Mar;24(3):245-9. doi: 10.1016/j.nmd.2013.11.007. Epub 2013 Nov 22.
Neuromuscul Disord. 2014.
PMID: 24332676
After adjusting for confounders and relative to the cohort, patients with MG had a 2.27-fold increased risk of developing lymphoid malignancies (HR=2.27, 95% CI=1.06-4.88) and a 118.47-fold increased risk of thymus cancer (HR=118.47, 95%=42.57-329.71). This populati …
After adjusting for confounders and relative to the cohort, patients with MG had a 2.27-fold increased risk of developing lymphoid malignanc …
Item in Clipboard
De novo hepatocellular carcinoma in a non-cirrhotic allograft 27 years after liver transplantation: A case report.
El-Domiaty N, Saliba F, Sebagh M, Salloum C, Vibert E, Azoulay D, Hamelin J, Cherqui D, Adam R, Samuel D.
El-Domiaty N, et al.
Am J Transplant. 2021 May;21(5):1953-1958. doi: 10.1111/ajt.16476. Epub 2021 Jan 23.
Am J Transplant. 2021.
PMID: 33382179
Free article.
Pretransplant assessment and explant liver pathology revealed no tumor. He developed an 8 cm mediastinal thymus cancer in 2014, a chronic myeloid leukemia in 2015 and a 16 mm renal cell carcinoma in 2017. ...The pathological report confirmed a moderately differentia …
Pretransplant assessment and explant liver pathology revealed no tumor. He developed an 8 cm mediastinal thymus cancer in 2014 …
Item in Clipboard
Cite
Cite